Thus, SUMOylation of SERCA2a activated via small molecules or enforced expression of SUMO1 with gene transfer may be a new therapeutic approach to treat heart failure.69 The SUMOylation of HSF2 mediated by SUMO‐1 was reported to attenuate myocardial hypertrophy. Here, SUMO1 is linked to cardiac hypertrophy.